Progesterone: Review of Safety for Clinical Studies

Experimental and Clinical Psychopharmacology

Volumn 15, Issue 5, 2007, Pages 427-444

  Goletiani, Nathalie V ^a   Keith, Diana R ^a   Gorsky, Sara J ^a  

^a MCLEAN HOSPITAL   (United States)

Author keywords

micronized progesterone; progesterone; synthetic progesterone

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE;

ARTICLE; DRUG ABUSE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG RESEARCH; DRUG SAFETY; DYSPHORIA; FATIGUE; FLUID RETENTION; HUMAN; SIDE EFFECT;

BIOLOGICAL AVAILABILITY; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; HUMANS; PROGESTERONE; PROGESTINS;

EID: 36049044777     PISSN: 10641297     EISSN: None     Source Type: Journal    
DOI: 10.1037/1064-1297.15.5.427     Document Type: Article

References (145)

1. Abrams L.S., Skee D., Natarajan J., and Wong F.A. Pharmacokinetic overview of Ortho Evra/Evra. Fertility and Sterility 77 2, Suppl. 2 (2002) S3-S12
2. Abu J., Brown L., and Ireland D. Endometrial adenocarcinoma following insertion of the levonorgestrel-releasing intrauterine system (Mirena) in a 36-year-old woman. International Journal of Gynecological Cancer 16 (2006) 1445-1447
3. Akhter H., Dunson T.R., Amatya R.N., Begum K., Chowdhury T., Dighe N., et al. A five-year clinical evaluation of Norplant contraceptive subdermal implants in Bangladeshi acceptors. Contraception 47 (1993) 569-582
4. Aktun H., Moroy P., Cakmak P., Yalcin H.R., Mollamahmutoglu L., and Danisman N. Depo-Provera: Use of a long-acting progestin injectable contraceptive in Turkish women. Contraception 72 (2005) 24-27
5. Andreen L., Sundstrom-Poromaa I., Bixo M., Andersson A., Nyberg S., and Backstrom T. Relationship between allopregnanolone and negative mood in postmenopausal women taking sequential hormone replacement therapy with vaginal progesterone. Psychoneuroendocrinology 30 (2005) 212-224
6. Apgar B.S., and Greenberg G. Using progestins in clinical practice. American Family Physician 62 (2000) 1839-1846 1849-1850
7. Archer D.F., Fahy G.E., Viniegra-Sibal A., Anderson F.D., Snipes W., and Foldesy R.G. Initial and steady-state pharmacokinetics of a vaginally administered formulation of progesterone. American Journal of Obstetrics and Gynecology 173 (1995) 471-478
8. Audet M.C., Moreau M., Koltun W.D., Waldbaum A.S., Shangold G., Fisher A.C., et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs. an oral contraceptive: A randomized controlled trial. Journal of the American Medical Association 285 (2001) 2347-2354
9. Backstrom T., Wahlstrom G., Wahlstrom K., Zhu D., and Wang M.D. Isoallopregnanolone: An antagonist to the anaesthetic effect of allopregnanolone in male rats. European Journal of Pharmacology 512 (2005) 15-21
10. Bales M.J., and Timpe E.M. Respiratory stimulant use in chronic obstructive pulmonary disease. Annals of Pharmacotherapy 38 (2004) 1722-1725
11. Basdevant A., Pelissier C., Conard J., Degrelle H., Guyene T.T., and Thomas J.L. Effects of nomegestrol acetate (5 mg/d) on hormonal, metabolic and hemostatic parameters in premenopausal women. Contraception 44 (1991) 599-605
12. Bernardi F., Pluchino N., Pieri M., Begliuomini S., Lenzi E., Puccetti S., et al. Progesterone and medroxyprogesterone acetate effects on central and peripheral allopregnanolone and beta-endorphin levels. Neuroendocrinology 83 (2006) 348-359
13. Blakeman P.J., Hilton P., and Bulmer J.N. Oestrogen and progesterone receptor expression in the female lower urinary tract, with reference to oestrogen status. BJU International 86 (2000) 32-38
14. Carmina E., and Lobo R.A. Evaluation of hormonal status. In: Strauss III J.F., and Barbieri R.L. (Eds). Yen and Jaffe's reproductive endocrinology: Physiology, pathophysiology, and clinical management. 5th ed. (2004), Elsevier, Philadelphia 939-964
15. Casanas-Roux F., Nisolle M., Marbaix E., Smets M., Bassil S., and Donnez J. Morphometric, immunohistological and three-dimensional evaluation of the endometrium of menopausal women treated by oestrogen and Crinone, a new slow-release vaginal progesterone. Human Reproduction 11 (1996) 357-363
16. Celayir S., Ilce Z., and Dervisoglu S. The sex hormone receptors in the bladder in childhood-I: Preliminary report in male subjects. European Journal of Pediatric Surgery 12 (2002) 312-317
17. Chakmakjian Z.H., and Zachariah N.Y. Bioavailability of progesterone with different modes of administration. Journal of Reproductive Medicine 32 (1987) 443-448
18. Christow A., Sun X., and Gemzell-Danielsson K. Effect of mifepristone and levonorgestrel on expression of steroid receptors in the human fallopian tube. Molecular Human Reproduction 8 (2002) 333-340
19. Cicinelli E., Ragno G., Cagnazzo I., Fanelli F., Vetuschi C., and Schonauer S. Progesterone administration by nasal spray. Fertility and Sterility 56 (1991) 139-141
20. Croxatto H.B. Mechanisms that explain the contraceptive action of progestin implants for women. Contraception 65 (2002) 21-27
21. Croxatto H.B. Progestin implants for female contraception. Contraception 65 (2002) 15-19
22. Cummings J.A., and Brizendine L. Comparison of physical and emotional side effects of progesterone or medroxyprogesterone in early postmenopausal women. Menopause 9 (2002) 253-263
23. de Lignieres B. Oral micronized progesterone. Clinical Therapeutics 21 (1999) 41-60
24. de Lignieres B., and Vincens M. Differential effects of exogenous oestradiol and progesterone on mood in post-menopausal women: Individual dose/effect relationship. Maturitas 4 (1982) 67-72
25. Dennerstein L., Spencer-Gardner C., Gotts G., Brown J.B., Smith M.A., and Burrows G.D. Progesterone and the premenstrual syndrome: A double blind crossover trial. British Medical Journal (Clinical Research Edition) 290 (1985) 1617-1621
26. DePaolo L.V. Attenuation of preovulatory gonadotrophin surges by epostane: A new inhibitor of 3 beta-hydroxysteroid dehydrogenase. Journal of Endocrinology 118 (1988) 59-68
27. de Wit H., Schmitt L., Purdy R., and Hauger R. Effects of acute progesterone administration in healthy postmenopausal women and normally-cycling women. Psychoneuroendocrinology 26 (2001) 697-710
28. Diaz S., Pavez M., Miranda P., Johansson E.D., and Croxatto H.B. Long-term follow-up of women treated with Norplant implants. Contraception 35 (1987) 551-567
29. Evans S.M., and Foltin R.W. Exogenous progesterone attenuates the subjective effects of smoked cocaine in women, but not in men. Neuropsychopharmacology 31 (2006) 659-674
30. Evans S.M., Haney M., and Foltin R.W. The effects of smoked cocaine during the follicular and luteal phases of the menstrual cycle in women. Psychopharmacology (Berlin) 159 (2002) 397-406
31. Fanchin R., De Ziegler D., Bergeron C., Righini C., Torrisi C., and Frydman R. Transvaginal administration of progesterone. Obstetrics and Gynecology 90 (1997) 396-401
32. Farinha A., Bica A., and Tavares P. Improved bioavailability of a micronized megestrol acetate tablet formulation in humans. Drug Development and Industrial Pharmacy 26 (2000) 567-570
33. Faundes A., Tejada A.S., Brache V., and Alvarez F. Subjective perception of bleeding and serum ferritin concentration in long-term users of Norplant. Contraception 35 (1987) 189-196
34. Finn D.A., Beadles-Bohling A.S., Beckley E.H., Ford M.M., Gililland K.R., Gorin-Meyer R.E., et al. A new look at the 5alpha-reductase inhibitor finasteride. CNS Drug Reviews 12 (2006) 53-76
35. Franz H.B., Wendler D., and Oettling G. Immunohistochemical assessment of steroid hormone receptors in tissues of the anal canal: Implications for anal incontinence?. Acta Obstetricia et Gynecologica Scandinavica 75 (1996) 892-895
36. Fraser I.S., and Kovacs G.T. The efficacy of non-contraceptive uses for hormonal contraceptives. Medical Journal of Australia 178 (2003) 621-623
37. Fraser I.S., Tiitinen A., Affandi B., Brache V., Croxatto H.B., Diaz S., et al. Norplant consensus statement and background review. Contraception 57 (1998) 1-9
38. Freeman E.W., Purdy R.H., Coutifaris C., Rickels K., and Paul S.M. Anxiolytic metabolites of progesterone: Correlation with mood and performance measures following oral progesterone administration to healthy female volunteers. Neuroendocrinology 58 (1993) 478-484
39. Freeman E.W., Weinstock L., Rickels K., Sondheimer S.J., and Coutifaris C. A placebo-controlled study of effects of oral progesterone on performance and mood. British Journal of Clinical Pharmacology 33 (1992) 293-298
40. Friess H., Buchler M., Kiesel L., Kruger M., and Beger H.G. LH-RH receptors in the human pancreas: Basis for antihormonal treatment in ductal carcinoma of the pancreas. International Journal of Pancreatology 10 (1991) 151-159
41. Gaver R.C., Pittman K.A., Reilly C.M., Smyth R.D., Goodson P.J., Fenzl E., et al. Bioequivalence evaluation of new megestrol acetate formulations in humans. Seminars in Oncology 12 Suppl. 1 (1985) 17-19
42. Gaytan F., Bellido C., Gaytan M., Morales C., and Sanchez-Criado J.E. Differential effects of RU486 and indomethacin on follicle rupture during the ovulatory process in the rat. Biology of Reproduction 69 (2003) 99-105
43. Germond M., Capelli P., Bruno G., Vesnaver S., Senn A., Rouge N., et al. Comparison of the efficacy and safety of two formulations of micronized progesterone (Ellios and Utrogestan) used as luteal phase support after in vitro fertilization. Fertility and Sterility 77 (2002) 313-317
44. Girdler S.S., Straneva P.A., Light K.C., Pedersen C.A., and Morrow A.L. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biological Psychiatry 49 (2001) 788-797
45. Gron G., Friess E., Herpers M., and Rupprecht R. Assessment of cognitive performance after progesterone administration in healthy male volunteers. Neuropsychobiology 35 (1997) 147-151
46. Hall J.E. Neuroendocrine control of the menstrual cycle. In: Strauss III J.F., and Barbieri R.L. (Eds). Yen and Jaffe's reproductive endocrinology: Physiology, pathophysiology, and clinical management. 5th ed. (2004), Elsevier, Philadelphia 195-211
47. Haukkamaa M., Laurikka-Routti M., and Heikinheimo O. Transdermal absorption of the progestin ST-1435: Therapeutic serum steroid concentrations and high excretion of the steroid in saliva. Contraception 44 (1991) 269-276
48. Henzl M.R. Norgestimate: From the laboratory to three clinical indications. Journal of Reproductive Medicine 46 (2001) 647-661
49. Henzl M.R., and Loomba P.K. Transdermal delivery of sex steroids for hormone replacement therapy and contraception: A review of principles and practice. Journal of Reproductive Medicine 48 (2003) 525-540
50. Hibbert, M. L., Stouffer, R. L., Wolf, D. P., & Zelinski-Wooten, M. B. (1996). Midcycle administration of a progesterone synthesis inhibitor prevents ovulation in primates. Proceedings of the National Academy of Sciences of the United States of America, 93, 1897-1901.
51. Inki P. Long-term use of the levonorgestrel-releasing intrauterine system. Contraception 75 Suppl. 6 (2007) S161-S166
52. Ishibashi H., Suzuki T., Suzuki S., Moriya T., Kaneko C., Takizawa T., et al. Sex steroid hormone receptors in human thymoma. Journal of Clinical Endocrinology and Metabolism 88 (2003) 2309-2317
53. Johansson E.D. Future developments in hormonal contraception. American Journal of Obstetrics and Gynecology 190 Suppl. 4 (2004) S69-S71
54. Jordan A. Toxicology of progestogens of implantable contraceptives for women. Contraception 65 (2002) 3-8
55. Kimzey L.M., Gumowski J., Merriam G.R., Grimes Jr. G.J., and Nelson L.M. Absorption of micronized progesterone from a nonliquefying vaginal cream. Fertility and Sterility 56 (1991) 995-996
56. Koubovec D., Ronacher K., Stubsrud E., Louw A., and Hapgood J.P. Synthetic progestins used in HRT have different glucocorticoid agonist properties. Molecular Cell Endocrinology 242 (2005) 23-32
57. Kuhl H. Comparative pharmacology of newer progestogens. Drugs 51 (1996) 188-215
58. Kumar D., Goodno J.A., and Barnes A.C. In vivo effects of intravenous progesterone infusion on human gravid uterine contractility. Bulletin of the Johns Hopkins Hospital 113 (1963) 53-56
59. Laurikka-Routti M., Haukkamaa M., and Heikinheimo O. A contraceptive vaginal ring releasing ethinyl estradiol and the progestin ST-1435: Bleeding control, serum steroid concentrations, serum lipids and serum chemistry. Contraception 42 (1990) 111-120
60. Laurikka-Routti M., Haukkamaa M., and Lahteenmaki P. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435. Fertility and Sterility 58 (1992) 680-684
61. Leonetti H.B., Longo S., and Anasti J.N. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstetrics and Gynecology 94 (1999) 225-228
62. Levine H., and Watson N. Comparison of the pharmacokinetics of crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women. Fertility and Sterility 73 (2000) 516-521
63. Little B.C., Matta R.J., and Zahn T.P. Physiological and psychological effects of progesterone in man. Journal of Nervous and Mental Disease 159 (1974) 256-262
64. Lo K.C., and Lamb D.J. The testis and male accessory organs. In: Strauss III J.F., and Barbieri R.L. (Eds). Yen and Jaffe's reproductive endocrinology: Physiology, pathophysiology, and clinical management. 5th ed. (2004), Elsevier, Philadelphia 367-387
65. Lobo R.A. Menopause and aging. In: Strauss III J.F., and Barbieri R.L. (Eds). Yen and Jaffe's reproductive endocrinology: Physiology, pathophysiology, and clinical management. 5th ed. (2004), Elsevier, Philadelphia 421-452
66. Luetjens C.M., Didolkar A., Kliesch S., Paulus W., Jeibmann A., Bocker W., et al. Tissue expression of the nuclear progesterone receptor in male non-human primates and men. Journal of Endocrinology 189 (2006) 529-539
67. Lundgren P., Stromberg J., Backstrom T., and Wang M. Allopregnanolone-stimulated GABA-mediated chloride ion flux is inhibited by 3beta-hydroxy-5alpha-pregnan-20-one (isoallopregnanolone). Brain Research 982 (2003) 45-53
68. Luukkainen T., Allonen H., Haukkamaa M., Holma P., Pyorala T., Terho J., et al. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study. Contraception 36 (1987) 169-179
69. MacNamara P., O'Shaughnessy C., Manduca P., and Loughrey H.C. Progesterone receptors are expressed in human osteoblast-like cell lines and in primary human osteoblast cultures. Calcified Tissue International 57 (1995) 436-441
70. Maxson W.S., and Hargrove J.T. Bioavailability of oral micronized progesterone. Fertility and Sterility 44 (1985) 622-626
71. Meggouh F., Lointier P., Pezet D., and Saez S. Status of sex steroid hormone receptors in large bowel cancer. Cancer 67 (1991) 1964-1970
72. Meggouh F., Lointier P., and Saez S. Sex steroid and 1,25-dihydroxyvitamin D3 receptors in human colorectal adenocarcinoma and normal mucosa. Cancer Research 51 (1991) 1227-1233
73. Meirik O., Fraser I.S., and d'Arcangues C. Implantable contraceptives for women. Human Reproduction Update 9 (2003) 49-59
74. Mello, N. K., Knudson, I. M., Kelly, M., & Mendelson, J. H. (2007). Effects of progesterone and testosterone on cocaine self-administration and cocaine discrimination by female rhesus monkeys. Manuscript in preparation.
75. Mesiano S., and Jaffe R.B. The endocrinology of human pregnancy and fetal-placental neuroendocrine development. In: Strauss III J.F., and Barbieri R.L. (Eds). Yen and Jaffe's reproductive endocrinology: Physiology, pathophysiology, and clinical management. 5th ed. (2004), Elsevier, Philadelphia 327-366
76. Micevych P., Sinchak K., Mills R.H., Tao L., LaPolt P., and Lu J.K. The luteinizing hormone surge is preceded by an estrogen-induced increase of hypothalamic progesterone in ovariectomized and adrenalectomized rats. Neuroendocrinology 78 (2003) 29-35
77. Moran M.H., Goldberg M., and Smith S.S. Progesterone withdrawal. II: Insensitivity to the sedative effects of a benzodiazepine. Brain Research 807 (1998) 91-100
78. Morville R., Dray F., Reynier J., and Barrat J. Biodisponibilite de in progesterone naturelle administree par vok orale. Mesure des concentrations du steroi'de dans ie plasma, l'endometre et ie tissu mammaire. [The bioavailability of natural progesterone given by mouth. Measurement of steroid concentrations in plasma, endometrium and breast tissue]. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction (Paris) 11 (1982) 355-363
79. Nakamura Y., Suzuki T., Inoue T., Tazawa C., Ono K., Moriya T., et al. Progesterone receptor subtypes in vascular smooth muscle cells of human aorta. Endocrine Journal 52 (2005) 245-252
80. Nelson A.L., and Katz T. Initiation and continuation rates seen in 2-year experience with same day injections of DMPA. Contraception 75 (2007) 84-87
81. Newman J.L., Thorne J.J., Batulis D.K., and Carroll M.E. Effects of menstrual cycle phase on the reinforcing effects of phencyclidine (PCP) in rhesus monkeys. Pharmacology, Biochemistry and Behavior 85 (2006) 584-591
82. Nillius S.J., and Johansson E.D. Plasma levels of progesterone after vaginal, rectal, or intramuscular administration of progesterone. American Journal of Obstetrics and Gynecology 110 (1971) 470-477
83. Niswender G.D. Molecular control of luteal secretion of progesterone. Reproduction 123 (2002) 333-339
84. Norethisterone and norethisterone acetate. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans 21 (1979) 441-460
85. N-Wihlbäck A.C., Sundström-Poromaa I., and Bäckström T. Action by and sensitivity to neuroactive steroids in menstrual cycle related CNS disorders. Psychopharmacology (Berlin) 186 (2006) 388-401
86. Oettel M., and Mukhopadhyay A.K. Progesterone: The forgotten hormone in men?. Aging Male 7 (2004) 236-257
87. Oettling G., and Franz H.B. Mapping of androgen, estrogen and progesterone receptors in the anal continence organ. European Journal of Obstetrics, Gynecology, and Reproductive Biology 77 (1998) 211-216
88. Pakarinen P., and Luukkainen T. Five years' experience with a small intracervical/intrauterine levonorgestrel-releasing device. Contraception 72 (2005) 342-345
89. Pechere-Bertschi A., and Burnier M. Gonadal steroids, salt-sensitivity and renal function. Current Opinion in Nephrology and Hypertension 16 (2007) 16-21
90. Peralta O., Diaz S., and Croxatto H. Subdermal contraceptive implants. Journal of Steroid Biochemistry and Molecular Biology 53 (1995) 223-226
91. Physicians' desk reference. 60th ed. (2006), Thomson PDR, Montvale, NJ
92. Pierucci-Lagha A., Covault J., Feinn R., Nellissery M., Hernandez-Avila C., Oncken C., et al. GABRA2 alleles moderate the subjective effects of alcohol, which are attenuated by finasteride. Neuropsychopharmacology 30 (2005) 1193-1203
93. Pluchino N., Luisi M., Lenzi E., Centofanti M., Begliuomini S., Freschi L., et al. Progesterone and progestins: Effects on brain, allopregnanolone and beta-endorphin. Journal of Steroid Biochemistry and Molecular Biology 102 (2006) 205-213
94. Pouly J.L., Bassil S., Frydman R., Hedon B., Nicollet B., Prada Y., et al. Luteal support after in-vitro fertilization: Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Human Reproduction 11 (1996) 2085-2089
95. Remohi J., Balmaceda J.P., Rojas F.J., and Asch R.H. The role of pre-ovulatory progesterone in the midcycle gonadotrophin surge, ovulation and subsequent luteal phase: Studies with RU486 in rhesus monkeys. Human Reproduction 3 (1988) 431-435
96. Rhen T., and Cidlowski J.A. Steroid hormone action. In: Strauss II J.F., and Barbieri R. (Eds). Yen and Jaffe's reproductive endocrinology: Physiology, pathophysiology, and clinical management. 5th ed. (2004), Elsevier, Philadelphia 155-174
97. Robustelli della Cuna G., Zanon P., Pavesi L., Preti P., Prada G.A., and Decensi A. An overview of clinical trials with high-dose medroxyprogesterone acetate (HD-MPA) in endocrine-related tumors other than breast cancer. Chemioterapia 5 (1986) 164-172
98. Romeo E., Brancati A., De Lorenzo A., Fucci P., Furnari C., Pompili E., et al. Marked decrease of plasma neuroactive steroids during alcohol withdrawal. Clinical Neuropharmacology 19 (1996) 366-369
99. Ronnerdag M., and Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system: A follow-up study over 12 years of continuous use. Acta Obstetricia et Gynecologica Scandinavica 78 (1999) 716-721
100. Rosen M.D., and Cedars M.I. Female reproductive endocrinology and infertility. In: Gardner D.G., and Shoback D. (Eds). Greenspan's basic and clinical endocrinology. 8th ed. (2007), McGraw-Hill, New York 502-561
101. Russo J., Ao X., Grill C., and Russo I.H. Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Research and Treatment 53 (1999) 217-227
102. Rylance P.B., Brincat M., Lafferty K., De Trafford J.C., Brincat S., Parsons V., et al. Natural progesterone and antihypertensive action. British Medical Journal (Clinical Research Edition) 290 (1985) 13-14
103. Sadeghi-Bazargani H., Ehdaeivand F., Arshi S., Eftekhar H., Sezavar H., and Amanati L. Low-dose oral contraceptive to re-induce menstrual bleeding in amenorrheic women on DMPA treatment: A randomized clinical trial. Medical Science Monitor 12 (2006) CR420-CR425
104. Schacter L., Rozencweig M., Canetta R., Kelley S., Nicaise C., and Smaldone L. Megestrol acetate: Clinical experience. Cancer Treatment Reviews 16 (1989) 49-63
105. Schindler A.E., Campagnoli C., Druckmann R., Huber J., Pasqualini J.R., Schweppe K.W., et al. Classification and pharmacology of progestins. Maturitas 46 Suppl. 1 (2003) S7-S16
106. Schumacher M., Guennoun R., Ghoumari A., Massaad C., Robert F., El-Etr M., et al. Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system. Endocrine Reviews 28 (2007) 387-439
107. Schweizer E., Case W.G., Garcia-Espana F., Greenblatt D.J., and Rickels K. Progesterone co-administration in patients discontinuing long-term benzodiazepine therapy: Effects on withdrawal severity and taper outcome. Psychopharmacology (Berlin) 117 (1995) 424-429
108. Shangold M.M., Tomai T.P., Cook J.D., Jacobs S.L., Zinaman M.J., Chin S.Y., et al. Factors associated with withdrawal bleeding after administration of oral micronized progesterone in women with secondary amenorrhea. Fertility and Sterility 56 (1991) 1040-1047
109. Simon J.A., Robinson D.E., Andrews M.C., Hildebrand III J.R., Rocci Jr. M.L., Blake R.E., et al. The absorption of oral micronized progesterone: The effect of food, dose proportionality, and comparison with intramuscular progesterone. Fertility and Sterility 60 (1993) 26-33
110. Simoncini T., Mannella P., Fornari L., Caruso A., Willis M.Y., Garibaldi S., et al. Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology 145 (2004) 5745-5756
111. Singh M. Mechanisms of progesterone-induced neuroprotection. Annals of the New York Academy of Sciences 1052 (2005) 145-151
112. Singh S., Sheppard M.C., and Langman M.J. Sex differences in the incidence of colorectal cancer: An exploration of oestrogen and progesterone receptors. Gut 34 (1993) 611-615
113. Sitruk-Ware R. New progestagens for contraceptive use. Human Reproduction Update 12 (2006) 169-178
114. Sitruk-Ware R. The levonorgestrel intrauterine system for use in peri- and postmenopausal women. Contraception 75 Suppl. 6 (2007) S155-S160
115. Sitruk-Ware R. Routes of delivery for progesterone and progestins. Maturitas 57 (2007) 77-80
116. Sivin I., Campodonico I., Kiriwat O., Holma P., Diaz S., Wan L., et al. The performance of levonorgestrel rod and Norplant contraceptive implants: A 5 year randomized study. Human Reproduction 13 (1998) 3371-3378
117. Soderpalm A.H., Lindsey S., Purdy R.H., Hauger R., and de Wit H. Administration of progesterone produces mild sedative-like effects in men and women. Psychoneuroendocrinology 29 (2004) 339-354
118. Sofuoglu M., Babb D.A., and Hatsukami D.K. Progesterone treatment during the early follicular phase of the menstrual cycle: Effects on smoking behavior in women. Pharmacology, Biochemistry and Behavior 69 (2001) 299-304
119. Sofuoglu M., Babb D.A., and Hatsukami D.K. Effects of progesterone treatment on smoked cocaine response in women. Pharmacology, Biochemistry and Behavior 72 (2002) 431-435
120. Sofuoglu M., Mitchell E., and Kosten T.R. Effects of progesterone treatment on cocaine responses in male and female cocaine users. Pharmacology, Biochemistry and Behavior 78 (2004) 699-705
121. Stadberg E., Westlund P., Landgren B.M., Aedo A.R., Cekan S.Z., and Mattsson L.A. Bioavailability of norethisterone acetate alone and in combination with estradiol administered in single or multiple oral doses to postmenopausal women. Maturitas 33 (1999) 59-69
122. Stanczyk F.Z. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Reviews in Endocrine & Metabolic Disorders 3 (2002) 211-224
123. Strauss III J.F. The synthesis and metabolism of steroid hormones. In: Strauss III J.F., and Barbieri R.L. (Eds). Yen and Jaffe's reproductive endocrinology: Physiology, pathophysiology, and clinical management. 5th ed. (2004), Elsevier, Philadelphia 125-154
124. Strauss III J.F., and Williams C.J. The ovarian life cycle. In: Strauss III J.F., and Barbieri R.L. (Eds). Yen and Jaffe's reproductive endocrinology: Physiology, pathophysiology, and clinical management. 5th ed. (2004), Elsevier, Philadelphia 213-253
125. Szarewski A. High acceptability and satisfaction with NuvaRing use. European Journal of Contraception and Reproductive Health Care 7 Suppl. 2 (2002) 31-39
126. Taubert H.D., and Haskins A.L. Intravenous infusion of progesterone in human females: Blood levels obtained and effect of labor. Obstetrics and Gynecology 22 (1963) 405-408
127. Tavaniotou A., Smitz J., Bourgain C., and Devroey P. Comparison between different routes of progesterone administration as luteal phase support in infertility treatments. Human Reproduction Update 6 (2000) 139-148
128. Tay P.Y., and Lenton E.A. The impact of luteal supplement on pregnancy outcome following stimulated IVF cycles. Medical Journal of Malaysia 60 (2005) 151-157
129. Tollan A., Oian P., Kjeldsen S.E., Eide I., and Maltau J.M. Progesterone reduces sympathetic tone without changing blood pressure or fluid balance in men. Gynecologic and Obstetric Investigation 36 (1993) 234-238
130. Tremollieres F.A., Strong D.D., Baylink D.J., and Mohan S. Progesterone and promegestone stimulate human bone cell proliferation and insulin-like growth factor-2 production. Acta Endocrinologica (Copenhagen) 126 (1992) 329-337
131. Unfer V., Casini M.L., Marelli G., Costabile L., Gerli S., and Di Renzo G.C. Different routes of progesterone administration and polycystic ovary syndrome: A review of the literature. Gynecological Endocrinology 21 (2005) 119-127
132. Uzunova, V., Sheline, Y., Davis, J. M., Rasmusson, A., Uzunov, D. P., Costa, E., et al. (1998). Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proceedings of the National Academy of Sciences of the United States of America, 95, 3239-3244.
133. van der Meer Y.G., van Loenen A.C., Loendersloot E.W., and Jaszmann L.J. Plasma progesterone levels after using high dose suppositories: A preliminary report. Pharmaceutical Science and Technology Today 4 (1982) 135-136
134. Vegeto E., Shahbaz M.M., Wen D.X., Goldman M.E., O'Malley B.W., and McDonnell D.P. Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Molecular Endocrinology 7 (1993) 1244-1255
135. von Eye Corleta H., Capp E., and Ferreira M.B. Pharmacokinetics of natural progesterone vaginal suppository. Gynecologic and Obstetric Investigation 58 (2004) 105-108
136. Wagenaar M., Vos P., Heijdra Y., Teppema L., and Folgering H. Comparison of acetazolamide and medroxyprogesterone as respiratory stimulants in hypercapnic patients with COPD. Chest 123 (2003) 1450-1459
137. Wang M., Seippel L., Purdy R.H., and Backstrom T. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: Study on serum pregnenolone, pregnenolone sulfate, 5 alpha-pregnane-3,20-dione and 3 alpha-hydroxy-5 alpha-pregnan-20-one. Journal of Clinical Endocrinology and Metabolism 81 (1996) 1076-1082
138. Westhoff C. Depot-medroxyprogesterone acetate injection (Depo-Provera): A highly effective contraceptive option with proven long-term safety. Contraception 68 (2003) 75-87
139. Wildemeersch D. New frameless and framed intrauterine devices and systems-An overview. Contraception 75 Suppl. 6 (2007) S82-S92
140. Wildemeersch D., and Rowe P.J. Assessment of menstrual blood loss in Belgian users of a new T-shaped levonorgestrel-releasing intrauterine system. Contraception 71 (2005) 470-473
141. Williams K., Fisher J.S., Turner K.J., McKinnell C., Saunders P.T., and Sharpe R.M. Relationship between expression of sex steroid receptors and structure of the seminal vesicles after neonatal treatment of rats with potent or weak estrogens. Environmental Health Perspectives 109 (2001) 1227-1235
142. Wren B.G., Champion S.M., Willetts K., Manga R.Z., and Eden J.A. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause 10 (2003) 13-18
143. Xiao Z.L., Pricolo V., Biancani P., and Behar J. Role of progesterone signaling in the regulation of G-protein levels in female chronic constipation. Gastroenterology 128 (2005) 667-675
144. Yen S.S.C. Neuroendocrinology of reproduction. In: Strauss III J.F., and Barbieri R.L. (Eds). Yen and Jaffe's reproductive endocrinology: Physiology, pathophysiology, and clinical management. 5th ed. (2004), Elsevier, Philadelphia 3-73
145. Zheng S.R., Zheng H.M., Qian S.Z., Sang G.W., and Kaper R.F. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant. Contraception 60 (1999) 1-8